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Objective. To assess prevalence, clinical characteristics, trends in treatment pattern, and outcome in patients with intracranial
vascular malformations (IVMs). Methods. Nationwide inpatient sample. Patients with the diagnosis of an IVM admitted to US
hospitals from 2000 to 2007. Results. In 58,051 IVM-related admissions (detection rate 2.4/100,000 person-years; mean age 49±17
years; 52% women) major diagnoses were intracranial hemorrhage (ICrH) in 15%, seizure 32%, ischemia 5%, and headache
9%. Procedures included surgery (13%), embolization (13%), radiation therapy (2%), aneurysm clipping (1%), and mechanical
ventilation (6%). Ventilation and ICrH were associated with death (2%), whereas ventilation, ICrH, surgery, seizure, and ischemia
were associated with unfavorable outcome (20%). IVM detection rate and hospital outcome remained stable over time, whereas
mean age and comorbid diagnosis of cerebral ischemia increased (ICrH and seizure decreased). Conclusion. IVMs are infrequent
and present in 1/6 patients with some form of ICrH. Overall, seizure is the dominant comorbid diagnosis (1/3 patients). IVMs are
equally prevalent among race-ethnic groups and are increasingly detected later in life. The inpatient care of IVM patients results
in death or discharge into specialized care in 1/5 patients.
1.Introduction
Although relatively infrequent, congenital intracranial vas-
cular malformations (IVMs) represent an important cause
of intracranial hemorrhage with potentially devastating
consequences for the patient [1, 2]. Brain arteriovenous mal-
formations (BAVMs) and cavernous malformations (CMs)
are the most important forms among IVMs. The detection
rate of BAVMs ranges between 1.1–1.4/100,000 person-
years and is approximately 2.2/100,000 person-years for all
other forms of IVMs, including CM, venous malformation
(VM), vein of Galen malformation, and dural AV ﬁstula,
respectively [2–4].
Current management of IVMs is an interdisciplinary
challenge, involving neurosurgery, interventional neurora-
diology, radiation therapy, and neurology. The potentially
deleterious eﬀects of IVM-related intracranial hemorrhage
(ICrH) and the risk of recurrent bleeds led to the current
paradigm of obliterating the lesion, if deemed feasible with
surgery, which appears logical and cause driven [5–7]. In
contrast, some large case series found that most patients
faired relatively well after the initial hemorrhage from
ruptured BAVMs when compared to other causes of ICrH
[8–11]. An ongoing multi center clinical trial, ARUBA, will
compare the clinical outcome in patients with unruptured
BAVMs randomized either into surgical interventional treat-
ment or medical observation (natural history) [12, 13].
Currently, the management patterns vary across centers
and may include patients with and without symptoms, with
or without intracranial hemorrhage, and with incidentally
found IVMs [5]. Speciﬁcally, BAVMs often undergo pre-
surgical embolization in an attempt to devascularize the
lesion for safer deﬁnitive surgery [6, 14]. Radiation therapy
is another adjunct treatment form and also a sole option for2 Stroke Research and Treatment
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lesions that are otherwise not accessible [14, 15]. Adding
to the complexity of the procedures and the overall risk,
multiple treatment sessions may be necessary and a small
rate of recurrence after angiographically conﬁrmed complete
removal has been reported [16]. The goals of the present
study are to determine the detection rate of IVMs, to assess
patient and clinical characteristics, and to analyze treatment
pattern and outcome in patients with IVMs admitted to US
hospitals. In addition, a trend analysis is performed on above
parameters and on hospital cost using nationwide data from
year 2000 to 2007.
2. Methods
The Nationwide Inpatient Sample (NIS) is part of the
Healthcare Cost and Utilization Project (HCUP) which
is sponsored by the Agency for Healthcare Research and
Quality (AHRQ) of the US Department of Health & Human
Services and represents the largest all-payer inpatient care
database in the USA [17]. Datasets from year 2000 to
2007 were analyzed that included 7.4–8.0 million hospital
admissions per year from 28 to 40 states and 994–1,044
nonfederal hospitals, respectively. This constitutes a 20%
representative and stratiﬁed sample of US hospitals. The NIS
contains only deidentiﬁed data.
Variables included demographic parameters, admission
type, length of stay, discharge disposition, death, hospital
location, and charges. In addition, relevant diagnoses and
procedures in the database were identiﬁed using the ICD-
9-CM system (The International Classiﬁcation of Diseases,
9th Revision, Clinical Modiﬁcation): adult patients (≥18
years) with IVM were selected using code 747.81 (Figure 1).
Intracranial hemorrhages were identiﬁed using codes 430,
431, and 432.x, seizure using code 345.xx, and headache
with 346.xx and 784.0, unruptured cerebral aneurysms with
437.3, and acute ischemic stroke with 433.xx and 434.xx,
respectively. Procedures were selected using codes 88.41
(cerebral angiogram), 39.72 and 39.79 (embolization), 01.59
(surgery), 92.3x (radiosurgery), 39.5x (aneurysm clipping),
and96.7x(mechanicalventilation).TheNIScollectsupto15
diagnoses and procedures for each admission. Thus, relevant
modes of presentation, including intracranial hemorrhage,
seizure, and headache were identiﬁed by selecting primary
diagnoses only in addition to diagnoses found at “ANY”
rank.
Analyses were weighted with provided discharge weight
data that are used to create national estimates. For the
trend analysis data were stratiﬁed into four two-year blocks.
Univariate analyses included frequency (absolute number
and %) and average values (SD; standard deviation) with re-
spective comparative analyses (χ2-test, t-test for independent
samples). In multivariate logistic regression models, the
risk (odds ratio and 95% conﬁdence interval; OR 95%-
CI) of death and unfavorable discharge outcome (death or
discharge, other than routine or to short-term hospital) was
determined with input of signiﬁcant and relevant variables
from the univariate analysis. In addition, outcome was as-
sessed for patients presenting with hemorrhage versus with-
out. Outcome was further stratiﬁed into one group under-
going surgery and the other without surgery. Furthermore,
factors were determined that were associated with hospital
charges in multivariate linear regression models. A statistical
test was considered signiﬁcant when P<0.05. All statistics
were calculated with SPSS 15.0 (Chicago, IL).Stroke Research and Treatment 3
3. Results
3.1. Detection Rate. In the years from 2000 to 2007 a total
of 58,051 admissions included the diagnosis of an IVM
(Table 1). This is approximately 0.02% of all admission (total
number of admissions n = 306,447,670) and results in an
annual hospital detection rate of approximately 2.4 IVM
patients per 100,000 person-years in the US (average USA
population 300 Million).
3.2. Patient Characteristics and Clinical Variables. Most
admissions were acute admissions (63%) (Table 1). In
average the primary diagnosis was ICrH in 11%, headache,
seizure, or cerebral ischemia in 13%, IVM in 46%, and
31% had other primary diagnoses. However, 28,760 (35%)
patients had none of the typical “symptoms,” including
ICrH, seizure, headache, or cerebral ischemia.
3.3. Procedures and Outcome. The most frequent procedure
was cerebral angiogram with 37%, followed by embolization
and surgery with 13% in each category (Table 1). In
72% none of above procedures was performed. Mechanical
ventilation was necessary in 6% of the admissions. The
average length of stay was 6 ± 8 days. In-hospital death
occurred in 2% of the patients and unfavorable outcome,
including death and outcome other than routine or short-
term hospital, was observed in 20%.
3.4. Risk of Death and Unfavorable Outcome. A total of 19
variables were studied for their association with outcome in
IVM patients (Table 2). The variables were chosen based on
statistical signiﬁcance in the univariate analysis and based
on their potential relevance in having an eﬀect on outcome.
Overall, mechanical ventilation (OR 20.3 [95%-CI 15.0–
27.3]) and ICrH (OR 2.9 [2.3–3.8]) were strongly associated
with in-hospital death (Table 2). Unfavorable discharge
outcomeshowedstrongpositiveassociationswithventilation
(OR 2.8 [2.4–3.2]), ICrH (OR 2.1 [1.8–2.3]), seizure (OR 1.6
[1.5–1.7]), acute ischemic stroke (OR 1.5 [1.4–1.8]), surgery
(OR 1.4 [1.2–1.6]), and unruptured ICA-aneurysm (OR 1.4
[1.1–1.7]).
3.5. Hemorrhagic Presentation and Surgery
3.5.1. Hemorrhagic versus Nonhemorrhagic Presentation.
Compared with patients with ICrH, patients without bleeds
wereyounger,morefrequentlywomenandWhite,weremore
often elective admissions, and presented more often with
ischemia, seizure, or headache, underwent more endovascu-
lar and radiosurgical interventions, and had a shorter length
of stay and better outcomes (Table 3/Figures 2(a) and 2(b)).
3.5.2. Hemorrhagic Presentation: Surgery versus No Surgery.
From 6,144 patients with ICrH 12.1% (n = 745) underwent
surgery. Compared with patient who did not undergo
surgery, patients with surgery were less frequently White, but
more often Asian, more often elective admissions, had more
parenchymal bleeds and ischemia, longer length of stay, and
worse outcomes (Table 3/Figures 2(a) and 2(b)).
3.5.3. Nonhemorrhagic Presentation: Surgery versus No Sur-
gery. From 51,873 patients without ICrH 13.1% (n =
6,697) underwent surgery. Compared with patient who did
not undergo surgery, patients with surgery were younger,
less frequently White or Black, but more often Hispanic,
more often elective admissions, had less frequently ischemia
or headache, endovascular treatment or radiosurgery, but
underwent more often aneurysm clipping, had longer length
of stay, and worse outcomes (Table 3/Figures 2(a) and 2(b)).
3.6. Cost. Hospital charges (Figure 3) increased from an
average charge of $32,355 ± 43,442 per admission in
2000/2001 to an average of $51,398 ± 16412 in 2006/2007.
The total charge increased from $415,876,303 in 2000/2001
to $843,533,680 in 2006/2007 during this period. This equals
an absolute increase of $427,657,377 and a relative increase
by 103%.
A total of 23 variables were included to determine
the association with hospital charges (Table 4). Major
determinants included length of stay, number of procedures,
embolization,andsurgery(r2 = 0.66;P<0.001).Inasecond
model only 8 variables were included that revealed similar
results as the ﬁrst model, but included “time” as a major
determinant (r2 = 0.62; P<0.001). The overall cost-to-
charge ratio was 0.5.
3.7. Trend Analysis. Over time there was an increase in the
number of IVM-related admissions, average age, proportion
of women, proportion of acute admissions, and number
of diagnoses per patient. Frequencies of cerebral ischemia
(stroke and TIA) and headache increased, whereas the
incidence of ICrH and seizure showed a downward trend.
Except for embolization, all other operative procedures were
performed less frequently over time. Although in-hospital
death rate remained stable, the proportion of unfavorable
discharge outcome increased over time.
3.8. Comparison with Population Estimates. Data from the
US Census 2000 showed similar population distribution
pattern compared with the NIS IVM sample: North-East
18.3%(versus19.1%),Midwest22.1%(versus22.2%),South
36.4 (versus 34%), and West 23.2% (24.7). The distribution
of rural, urban, and urban academic centers were similar
across all four US regions (Figure 4). The racial-ethnic
distributions in the NIS IVM-sample match the data from
the US Census 2000 (Figure 5).
4. Discussion
4.1.EpidemiologyandClinicalFeatures. Basedontheaverage
frequency of ICrH of 11% as the primary diagnosis and
assuming 50–62% of adult BAVM patients present without
hemorrhage initially [3, 11], the crude estimate of “inciden-
tal”BAVMswouldbeapproximately22–27%oftheNISIVM
sample, that is, approximately 1600–2000 patients per year.
With consideration of multiple admissions—the NIS does
not allow the identiﬁcation of multiple admissions—BAVM-
related admissions may be much higher. Among other IVMs
than AVMs, cerebral CMs and VMs (often associated with4 Stroke Research and Treatment
Table 1: Univariate statistics.
Year 2000/2001 2002/2003 2004/2005 2006/2007 P Total
Number of IVM-related admissions n = 13,500 n = 14,242 n = 13,331 n = 16,977 58,051
Total number of admissions 73,605,206 76,024,680 77,825,620 78,992,164 306,447,670
Age, years (SD) 48.3 (17.1) 47.8 (17.4) 49.2 (17.2) 50.1 (17.3) <0.001 48.9 (17.3)
Women (%) 51.5 51.8 51.7 54.2 <0.001 52.4
Admission type (%) <0.001
Emergent 42 39.7 49.5 51 46
Urgent 18.1 18.3 15.6 15.9 16.9
Elective 39.9 41.8 34.5 32.8 37
Emergent and urgent 60.1 58 65.1 66.9 62.9
Disposition (%) <0.001
Routine 74.7 77.5 74.1 72.8 74.7
Short-term hospital 5 3.7 4.1 4.6 4.4
Another type facility 13.4 11.2 11.9 13.4 12.5
Home health care 4.7 4.9 6.3 6.5 5.7
Against medical advice 0.3 0.6 1.1 0.8 0.7
Died 1.9 2 2.4 1.8 0.005 2
Bad outcome∗ 20.3 18.7 21.7 22.5 <0.001 20.9
Length of stay, days 5.9 (8.2) 5.4 (8.3) 5.4 (7.2) 5.4 (8.8) <0.001 5.5 (8.2)
Number of diagnoses, any 4.9 (3.1) 5.2 (3.3) 5.9 (3.5) 6.8 (4.2) <0.001 5.8 (3.6)
Number of procedures, any 2.0 (2.1) 1.9 (2.0) 1.8 (2.0) 2.0 (2.4) <0.001 2.0 (2.2)
Race <0.001
White 69.0 67.9 69.6 64.3 67.5
Black 10.9 12.1 12.1 12.4 11.9
Hispanic 11.9 13.0 12.0 15.6 13.2
Asian 4.7 3.3 3.0 3.4 3.6
Native American 0.3 0.3 0.3 1.1 0.5
Other 3.1 3.3 3.0 3.2 3.1
Speciﬁc diagnosis all ranks
Any ICrH 17.5 14.0 14.8 13.7 <0.001 14.9
SAH 5 4.0 4.3 4.5 0.001 4.4
ICH 11.9 9.2 9.5 8.4 <0.001 9.7
Other ICrH 1.4 1.5 1.6 1.8 0.068 1.6
Seizure 33.8 32.5 30.0 31.1 <0.001 31.8
Headache 7.1 7.8 10.1 11.7 <0.001 9.3
Acute ischemic stroke 5.9 6.1 7.2 7.9 <0.001 6.8
TIA 2.1 2.1 2.7 3.1 <0.001 2.5
Primary speciﬁc diagnosis only 72.1 71.6 66.5 65.2 <0.001 68.6
Any ICrH 12.6 9.3 11.4 9.4 <0.001 10.6
Seizure 5.7 5.1 5.6 7.0 <0.001 5.9
Headache 1.4 1.5 2.4 1.9 <0.001 1.8
Acute cerebral ischemia 2.4 2.4 3.5 4.1 <0.001 3.1
TIA 1.6 1.5 1.7 2.0 0.004 1.7
IVM 48.4 51.8 41.9 40.8 <0.001 45.5
Intracranial ICA aneurysm, unruptured 2.5 2.7 2.8 2.7 0.305 2.7
Procedures
Cerebral angiogram 39.7 38.8 34.8 34.9 <0.001 37.0
Embolization —† 15.5 17.4 18.4 <0.001 13.4Stroke Research and Treatment 5
Table 1: Continued.
Year 2000/2001 2002/2003 2004/2005 2006/2007 P Total
Number of IVM-related admissions n = 13,500 n = 14,242 n = 13,331 n = 16,977 58,051
Surgery 14.9 12.9 11.3 12.3 <0.001 12.8
Radiosurgery 2.5 3.3 1.4 0.7 <0.001 1.9
Aneurysm clipping 1.9 1.3 1.2 1.2 <0.001 1.4
Embolization, and surgery 0.1 1.2 1.6 2.5 <0.001 1.4
No procedure 80.1 68.6 70.8 70.2 <0.001 72.2
Mechanical ventilation, all durations 5.4 4.8 5.8 5.9 <0.001 5.5
<96 hours 3.2 2.5 3.4 3.9 <0.001 3.3
≥96 hours 2.4 2.3 2.4 2.0 0.057 2.3
∗Death, another type facility, or home health care. †1%, misrepresentative ﬁgure, likely due to false or not coding. Standard deviation in parenthesis.
Abbreviations: ICrH: intracranial hemorrhage, SAH: subarachnoid hemorrhage, ICH: intracerebral hemorrhage, TIA: transient ischemic attack, IVM:
intracranial vascular malformation, ICA: internal carotid artery.
Table 2: Risk of Death and Unfavorable Outcome∗.
Death Unfavorable Outcome
OR 95%-CI P OR 95%-CI P
Age 1.02 (1.02–1.03) <0.001 1.04 (1.04-1.04) <0.001
Elective admission 0.65 (0.47–0.90) 0.010 0.82 (0.75–0.90) <0.001
Women 1.16 (0.93–1.45) 0.191 1.11 (1.03–1.20) 0.005
Length of stay 0.96 (0.95–0.97) <0.001 1.08 (1.07–1.08) <0.001
Number of procedures 1.13 (1.07–1.19) <0.001 1.06 (1.03–1.08) <0.001
White race 1.07 (0.84–1.37) 0.585 0.99 (0.90–1.07) 0.738
ICrH, any type 2.93 (2.27–3.80) <0.001 2.06 (1.85–2.30) <0.001
Seizure 1.33 (1.05–1.68) 0.020 1.59 (1.46–1.72) <0.001
Headache 0.25 (0.10–0.59) 0.002 0.70 (0.60–0.81) <0.001
ICA aneurysm, unruptured 1.91 (1.08–3.40) 0.027 1.38 (1.09–1.74) 0.007
Acute cerebral ischemia 0.98 (0.65–1.49) 0.942 1.55 (1.36–1.76) <0.001
Cerebral angiography 0.27 (0.20–0.37) <0.001 0.62 (0.56–0.69) <0.001
Embolization 1.54 (1.00–2.35) 0.049 0.90 (0.77–1.04) 0.163
Surgery 1.04 (0.74–1.46) 0.834 1.38 (1.21–1.58) <0.001
Radiosurgery 0.00 — 0.994 0.50 (0.31–0.81) 0.005
Aneurysm clipping 0.47 (0.18–1.20) 0.115 0.44 (0.31–0.62) <0.001
Ventilation 20.26 (15.01–27.34) <0.001 2.77 (2.37–3.25) <0.001
Hospital bed size 1.13 (1.00–1.29) 0.057 1.07 (1.02–1.12) 0.002
Hospital location/teaching 0.94 (0.81–1.09) 0.397 1.07 (1.01–1.12) 0.016
∗Goodness of ﬁt model summary: Death (Nagelkerke R2 = 0.342), Unfavorable Outcome (Nagelkerke R2 = 0.281).
Abbreviations: 95%-CI: 95% Conﬁdence Interval, ICrH: intracranial hemorrhage, ICA: internal carotid artery.
each other) are more frequent, but relatively benign diseases
that may present with signs of new or old hemorrhage
previously left undetected due to lacking symptoms [18, 19].
Vein of Galen malformations are prevalent in childhood and
AV ﬁstula mostly present without a bleed [20].
The ICD-9 coding system is not speciﬁc in terms of
type of congenital cerebrovascular malformation. Thus, the
estimate on the incidence and prevalence of IVM subtypes
can only be crude. However, our estimate on the average
annual detection rate of 2.24 IVMs per 100,000 patient-
years is similar to ﬁndings from previous population-based
studies, such as from Olmsted County in Minnesota [21]
and the New York Islands [3], USA, and Scotland [2], UK.
Hereby, detection rates for BAVMs range from 1.11–1.34 per
100,000 person-years, for CMs from 0.17–0.57 per 100,000
person-years, for VMs from 0.41–0.44 per 100,000 person-
years, for dural AVMs from 0.15-0.16 per 100,000 person-
years, and for all IVMs from 1.82–2.3 per 100,000 person-
years.
With increasing utilization of brain imaging, such as CT
and MRI, more IVMs are found incidentally than before [3,
19]. However, symptoms, including seizure, headache, focal
and global neurological deﬁcits, and tinnitus, among others,
account for the detection of a signiﬁcant proportion of6 Stroke Research and Treatment
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Figure 2: (a) Risk of death. (b) Risk of unfavorable outcome.
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BAVMs(79–85%),CMs(40–43%),VMs(7–14%),anddural
AV ﬁstulas (85–100%) [2, 21]. Prospective studies found
that patients with BAVMs presented with ICrH, seizure,
headache, and focal neurological deﬁcits in 38–71%, 24–
40%, 5–14%, and 5–20%, respectively [22–25]. When our
ﬁndings on the frequency of ICrH (11%), seizure (6%),
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Figure 5: Racial and ethnic distribution.
headache (2%), and cerebral ischemia (5%) are translated
into relative proportions, they result in 46%, 25%, 8%, and
21%, respectively.
4.2. Treatment and Outcome. The multivariate analyses
showed that mechanical ventilation had the highest associ-
ation with death or unfavorable outcome. A plausible way of
interpretation is that ICrH and surgery, both with negative
associations with outcome, would necessitate intensive med-
ical care like for any patient in a critical condition. However,
seizure,ischemicstroke,andunrupturedaneurysmwerealso
signiﬁcantly associated with unfavorable outcome some of
which might occur concurrently with hemorrhage, but may
also be unrelated to it.
The clinical outcome after BAVM-related hemorrhage
appears to be more favorable compared with the outcome
after primary intracerebral hemorrhage (ICH) [8, 9]. Death
rates following BAVM-related bleeds range between 0–11%
(versus 50% after ICH) and short- (30 days) and medium-
term (one year) functional outcome has been observed to be
relatively favorable with a median NIHSS score of 1 (versus
median NIHSS of 12) and median Rankin Scale (RS) score of
2 (versus median RS of 6), respectively.Stroke Research and Treatment 9
Table 4: Determinants of hospital charges.
(a)
Model 1 Model 2
Unstd.
Coeﬃ-
cientsB
Standard
Error
Std.
coeﬃcientsβ
t P
Unstd.
Coeﬃ-
cientsB
Standard
Error
Std.
coeﬃcientsβ t P
Age (y) 61.48 11.49 0.0200 5.3514 0.00000
Elective admission 1763.74 424.92 0.0160 4.1508 0.00003
In-hospital death 12044.56 1339.92 0.0317 8.9890 0.00000
Women −669.94 351.65 −0.0063 −1.9052 0.05677
Length of stay (d) 3613.12 28.99 0.5026 124.6288 0.00000 3412.81 22.53 0.4535 151.5009 0.00000
#D i a g n o s e s −287.82 61.42 −0.0199 −4.6863 0.00000
# Procedures 7049.92 118.25 0.2800 59.6181 0.00000 8824.37 92.78 0.3215 95.1101 0.00000
Time (year) 6169.46 232.79 0.0888 26.5024 0.00000 5677.02 137.73 0.1095 41.2199 0.00000
Median income 847.15 156.29 0.0177 5.4205 0.00000
ICrH 2804.75 931.44 0.0182 3.0112 0.00260
ICA aneurysm,
unruptured 1300.84 1135.07 0.0039 1.1460 0.25179
Acute ischemia 530.73 693.29 0.0026 0.7655 0.44397
Seizure −60.35 414.97 −0.0005 −0.1454 0.88438
Headache 1414.91 636.16 0.0082 2.2241 0.02615
Angiography 1372.53 431.61 0.0124 3.1800 0.00147
Embolization 29192.74 534.78 0.2086 54.5888 0.00000 29502.47 473.73 0.1707 62.2773 0.00000
IVM surgery 26550.75 608.40 0.1564 43.6403 0.00000 27449.01 488.44 0.1553 56.1973 0.00000
Radiosurgery 27182.37 1354.84 0.0682 20.0632 0.00000 16798.46 1122.82 0.0397 14.9609 0.00000
Aneurysm clip 27896.46 1678.19 0.0573 16.6230 0.00000 17164.04 1341.84 0.0338 12.7914 0.00000
Ventilation 12209.90 933.97 0.0518 13.0731 0.00000
ICrH primary diagn. 3325.46 1054.94 0.0187 3.1523 0.00162
Seizure primary
diagnosis 1473.41 787.55 0.0068 1.8709 0.06137
Headache primary
diagnosis 921.68 1334.31 0.0025 0.6908 0.48972
Constant −26640.78 1063.46 −25.0510 0.00000 −17986.64 416.53 −43.1820 0.00000
(b)
Adjusted R square df1 df2 Sig. F
Change Durbin-Watson
Model
1 0.6648 23 31610 0.0000 0.3258
Model
2 0.6161 8 56205 0.0000 0.3172
Abbreviations: Unstd.: unstandardized, Std.: standardized, #: number of, ICrH: intracranial hemorrhage, ICA: internal carotid artery, IVM: intracranial
vascular malformation.
Because of the negative associations with outcome and
because it is diﬃcult to tell which IVM subtype was treated
in our sample, we performed a more thorough analysis
based on the presence of ICrH (primary diagnosis) and
on whether surgery was performed or not. Overall, 9%
of the patients with ICrH died and 42% had unfavorable
discharge outcome. Among patients without hemorrhage
0.9% died and 17% had unfavorable outcome. The odds
for death and bad outcome were highest with the presence
of ICrH. Interestingly, surgery was linked to higher odds
for death in patients with bleeds and to higher odds for
bad outcome in both, bled and unbled patients. Whether
this indicates that the most severely aﬀected patients and
challenging IVMs are selected for surgery or whether surgery
itself poses a greater risk to the patient, regardless of the
integrity of the IVM, cannot be derived from our data.10 Stroke Research and Treatment
This may simply reﬂect the fact that surgery has a known
complication and risk proﬁle that may be oﬀset by a decrease
in potential morbidity and mortality from a treated IVM
over the remaining life of the individual. Such discounting
of the beneﬁcial eﬀects of surgical excision of IVMs in an
eﬀort to qualify the ﬁnding of surgery as an independent
predictor of bad outcome and death is beyond the scope
of this analysis. The data may, however, in part reﬂect the
current heterogeneous center-speciﬁc management pattern
of, speciﬁcally, BAVMs which remains a challenge and is
subject to ongoing studies [12, 26]. Ongoing and future
studies may and ought to give better insights to the rate
and degree of recovery from invasive therapies in unbled
patients in order to distinguish temporary from permanent
functional deﬁcits. It is, nevertheless, important to note that
among patients admitted to US hospitals with the diagnoses
of an IVM and ICrH, almost 1/10th will die and 2/5th will
either die or be discharged to long-term health care facilities
or home with home health care. Even more striking is the
fact that among patients with the diagnosis of an IVM and
without the presence of ICrH, only 1% will die, but still
almost 1/6th will either die or be discharged with specialized
medical care. Overall, 1/5th of all IVM-related admissions
will either die or be discharged with long-term care.
4.3. Trend. The comparison of our results with the US
consensus data from 2000 suggests that IVMs are equally
distributed among racial and ethnic groups and gender
groups. It is interesting, however, that the average age
increased from 48 ±17 years to 50 ±17 years over the study
period (8 years). Assuming stable IVM detection rates [2–
4] this could reﬂect general aging of the US population and
mean that IVMs are now detected later in life. Perhaps, the
overall improvement of vascular preventive management,
such as treatment of hypertension, smoking cessation, and
healthier life style, allows IVMs to remain undetected for a
longer period of time. The decrease in the rate of ICrH may
be an indicator for such improvements while the rates for
seizure and headache remained relatively stable. However,
the rate of cerebral ischemic events increased which might be
anageandgendereﬀectoutweighingtheeﬀectsofpreventive
measures. Also, more patients with IVMs present now in
an emergent or urgent setting, that is, less electively. This
may indicate that while IVMs remain longer silent, once
they become symptomatic the clinical picture is relatively
dramatic. The trend in the management of IVMs, however, is
less invasive in diagnosis (less frequent cerebral angiograms)
and therapy (less frequent surgery, but more endovascular
therapy). However, radiation therapy also decreased over
time. The latter might be due to the increasing shift of
radiationtherapyintotheoutpatientsettingwhichisnotpart
of the NIS.
The cost of inpatient IVM management in the US
doubled over the 8 years from approximately $200 million
in years 2000/2001 to $400 million in years 2006/2007. This
is a true increase in cost as the cost-to-charge ratio remained
stable at approximately 0.5. Additional factors signiﬁcantly
associated with charges include length of stay, number
of procedures, and the main procedures, surgery, and
endovascular therapy. In aggregate, the management of non-
hemorrhagic patients (primary diagnosis only) accounted
for 80% ($1.7 billion) of the total charges over the study
period. With an average of almost $300 million of inpatient
charges per year, the management of IVMs has economic
signiﬁcance in public health. Not included are costs from the
outpatient setting and lost productivity [27].
4.4. Limitations. The main limitation is the fact that the
ICD-9 coding system summarizes all IVMs into a single
code. It is therefore diﬃcult, if not impossible, to distinguish
between IVM subtypes. To alleviate this limitation we
performed further selections based on published epidemi-
ological and clinical data (frequency, clinical presentation,
and ICrH) and by focusing on the primary diagnostic code
whenanalyzingpresentingsymptoms.Intermsofthedesign,
this study is primarily a cross-sectional study. The main
disadvantage is that the results can provide only a “snapshot
in time” of IVMs and its management. This design is not
ideally suited for answering questions related to disease
processorforrevealingcausalrelationshipsbetweendiseases.
Second, our study also has characteristics of a case-control
study, albeit unmatched, as we compare groups with and
without hemorrhage and groups with and without surgery
with each other. Other limitations include unidentiﬁable
multiple admissions, incomplete clinical and anatomical
data, for example, severity of symptoms, angioarchitecture,
laboratory and imaging data, and unknown magnitude of
misclassiﬁcations. Finally, because the NIS sample represents
nationwide inpatient treatment, it may not reﬂect the true
incidence or prevalence of IVMs in the general population.
However, there are also unique advantages of analyzing
the NIS, a source with a large number of cases resulting in
an impressive database with 6–8 million admissions per year
and with its wealth of information. In addition, because of
the representative nature of the NIS the “snapshot in time”
becomes “the big picture” for USA hospital management
of medical conditions which may give unique insides into
rare diseases such as IVMs. NIS data is also well suited
for hypothesis generation, especially with trend data, that
certainly requires proof in well-designed prospective and
longitudinal studies. The introduction of ICD-10 will allow
better diﬀerentiation between the various IVM subtypes.
5. Conclusions
IVMs are infrequent, equally prevalent among racial-ethnic,
and gender groups and present in 1/6 patients with some
form of ICrH. Overall, seizure is the dominant comorbid
diagnosis (1/3 patients). IVMs are now increasingly detected
later in life. The short-term outcome of IVM inpatient care
has not markedly changed over almost a decade, resulting in
death or discharge into specialized care in 1/5 patients.
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